Blinatumomab and MRD-related outcomes. (A) The median and 3-year OS of blinatumomab 1 recipients (n = 122) according to TP2 MRD were as follows: MRD⁻ (n = 85), not reached and 89% (95% CI, 82-77); MRD⁺ (n = 37), 24.5 months and 49% (95% CI, 31-76); P = .00029. (B) The 3-year OS of blinatumomab recipients (n = 122) according to a combined TP2 and TP3 MRD analysis (excluding a single TP2 MRD^–/TP3 MRD⁺ patient) was as follows: TP2/TP3 MRD^– (n = 78), 88% (95% CI, 81-95); TP2 MRD⁺/TP3 MRD^– (n = 23), 43% (95% CI, 22-83); TP2/TP3 MRD⁺ (n = 7), 80% (95% CI, 52-100); P = .00097. In the latter group (n = 7), 4 patients had KMT2A⁺ ALL, 3 had CNA⁺ ALL, but none had Ph-like ALL (supplemental Table 8 for details). (C) The 3-year OS of all CR patients according to intended risk-oriented postremission strategy (ITT) was as follows: chemotherapy (n = 72), 91% (95% CI, 84-98); allo-HSCT (n = 60), 59% (95% CI, 46-77); P = .0029. (D) The 3-year OS of all CR patients receiving blinatumomab 1 according to intended risk-oriented postremission strategy (ITT) was as follows: chemotherapy (n = 70), 92% (95% CI, 85-99); allo-HSCT (n = 52), 65% (95% CI, 51-83). (E) The 3-year OS of allo-HSCT–eligible patients (n = 60) according to time-dependent HSCT realization (Simon-Makuch statistics) was as follows: HSCT, 69% (95% CI, 52-92) vs no HSCT, 38% (95% CI, 22-63); P = .0324. (F) The 3-year CIR and NRM in CR patients (n = 132) were as follows: CIR, 28.2% (95% CI, 19.7-36.6); and NRM, 7.2% (95% CI, 2.3-12.1).